The purpose of this study is to develop transcranial magnetic stimulation (TMS), specifically TMS at a frequency known as theta burst stimulation (TBS), to see how it affects the brain and changes the brain's response to alcohol-related pictures. TMS and TBS are stimulation techniques that use magnetic pulses to temporarily excite specific brain areas in awake people (without the need for surgery, anesthetic, or other invasive procedures). TBS, which is a form of TMS, will be applied over the medial prefrontal cortex, (MPFC), which has been shown to be involved with drinking patterns and alcohol consumption. This study will test whether TBS can be used as an alternative tool to reduce the desire to use alcohol and reducing the brain's response to alcohol-related pictures.
Many adolescents experience traumatic events, such as child abuse, physical or sexual assault, or witnessing violence. Teens who experience trauma are more likely to have problems with substance use and risky sexual activity. We want to understand how parents can support their teens and help keep them safe after traumatic events.
Alcohol Use Disorder (AUD) is a risk factor for Alzheimer's Disease (AD), but more research is needed to identify the potential mechanisms underlying this risk. The present study will use fMRI to examine brain network profiles in mid-life AUD. The goal is to develop techniques to assess risk for Alzheimer's Disease and related dementias. Participation includes cognitive testing and MRI scanning.
This study will examine the neural circuitry associated with craving, behavioral disinhibition, and threat-reactivity. The study will involve 2 visits. During the first visit, participants will complete questionnaires and interviews in a private room and do some tests to measure alcohol use. During the second visit, participants will complete a neuroimaging scan of their brain.
This study will examine the efficacy of intranasal oxytocin versus placebo in combination with Alcohol Behavioral Couples Therapy (ABCT) to reduce alcohol use disorder severity. We will also use observational coding and neuroimaging to examine behavioral and neural mechanisms underlying treatment outcomes.
The purpose of this study is to gather feedback to inform the development of a web-based tool that provides screening and education about alcohol use following interpersonal violence. People who have experienced sexual assault or domestic violence in the last year and drink alcohol, or are currently in treatment for alcohol use, will be asked to provide feedback about a web-based tool for alcohol use. 60-minute interviews will be conducted and will involve viewing the content of the web-based tool and providing feedback. Additionally, feedback given during interviews will be analyzed and then individuals who have used the web-based tool will complete a survey following the tool use if they report using substances.
The purpose of this study is to evaluate the efficacy of the medication N-acetylcysteine (NAC) to help young people with alcohol use disorder. NAC is an over-the-counter supplement and antioxidant that has been approved by the Food and Drug Administration (FDA) in adults and children for other uses, but has not been approved by the FDA for treatment of alcohol use disorder. All participants will receive brief alcohol counseling during the 8 weeks of medication treatment. Volunteers ages 13-20 are needed for this study.
This Charleston Alcohol Research Center (ARC) pilot study seeks to provide the preliminary validation of a novel natural rewards fMRI paradigm which may be used in the development and/or evaluation of alcohol addiction medication treatments. Specifically, individuals with alcohol use disorder (AUD) and social drinkers will be recruited for a magnetic resonance imaging (MRI) study which will include magnetic resonance spectroscopy, an alcohol cue task, and this novel natural rewards paradigm which examines brain response to social reward and food. Invited participants will complete an initial screening diagnostic assessment visit at the Medical University of South Carolina, which will consist of clinical interviews with research staff, questionnaires, and labs. If still eligible, participants will be invited for a second appointment which will include additional clinical measures, questionnaires, and an MRI scan. This study is confidential and participants will be compensated for participating.
The proposed study will employ treatment-seeking AUD individuals who will be randomly assigned to receive either 15 mg of rapamycin (sirolimus) or placebo immediately after the first of two alcohol cue exposure sessions scheduled to occur on consecutive days. Subjective responses (i.e., craving) and physiological (heart rate & skin conductance) reactivity will be obtained before, during and after cue presentations in both sessions. The durability of any observed treatment effects will be assessed in a Follow-up session performed approximately 10 days following completion of the second session. Treatment effects on self-report measures of drinking behavior during the approximately 10 days preceding the Follow-up session will also be assessed.
The purpose of this study is to evaluate the potential mechanism of action and the safety of GET73, a new drug under development for the reduction of craving and drinking in alcohol dependent individuals. The study involves five to six visits over a three to four week period, including one to two assessment visits and two visits during which participants will be assigned to take, in a double-blinded fashion, both GET73 and a placebo (two visits during each condition). During three of these visits, participants will undergo a one-hour MRI scan. Compensation is available for qualified participants.